tbuckley/cabot-search huggingface dataset:
Abstract 504: Circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs) are superior to CA 15-3 in predicting tumor burden, patients response to treatment and overall survival (OS) rates in metastatic breast cancer patients from Egypt
Authors: Abdel-Rahman N. Zekri, Abeer A. Bahnassy
Journal: Cancer Research (2016)

Abstract Background: Monitoring of tumor burden in patients with metastatic breast cancer (mBC) is crucial to determine response to treatment. In addition to radiological procedures and serological biomarkers, circulating, tumor cells (CTCs) are now used to assess the tumor burden and patients’ response to treatment. The circulating cell-free tumor DNA (ctDNA) harboring tumor-specific aberrations has not been properly assessed yet. Methods: 100 Egyptian patients with locally mBC were assessed for CA 15-3 levels, CTCs number by flowcytometry (FCM) confirmed by RT-PCR (CK and mammaglobin expression), and for ctDNA. The results of the three techniques were compared to the radiographic imaging of tumors, patients response to treatment and overall survival (OS) rates. Paraffin blocks for 40 tumor samples, obtained from the studied patients (20 non-responders and 20 responders) were used to detect p53 gene mutations exons 5-9. CA 15-3 levels and CTC numbers were measured at the same time intervals. Results: Somatic mutations of p53 were detected in 23/40 (57.5%) sequenced tumors. ctDNA showing the identified mutations in tumor samples, was detected in 78 cases (78%) with high dynamic range. CTCs&amp;gt;4/7.5ml blood were present in 57 out of the 78 (73.1%) ctDNA positive cases, and CA 15-3 was detected in 30 (38.5%) cases. Changes in ctDNA levels and CTCs&amp;gt;4 correlated significantly with the tumor burden (p = 0.034), patients response to treatment (p&amp;lt;0.01), and lower OS rates (p = 0.034&amp;p = 0.01; respectively). CTCs number and ctDNA levels showed higher correlation with changes in tumor burden, compared to CA 15-3 (p&amp;lt;0.001 versus p = 0.046). However, ctDNA provided the earliest measure of treatment response in most of the patients (53%). Conclusions: ctDNA is an informative, highly sensitive and specific biomarker that could be used to monitor tumor burden in mBC. Together with enumeration of CTCs they can predict tumor response and OS in mBC patients with high accuracy. Citation Format: Abdel-Rahman N. Zekri, Abeer A. Bahnassy. Circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs) are superior to CA 15-3 in predicting tumor burden, patients response to treatment and overall survival (OS) rates in metastatic breast cancer patients from Egypt. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 504.
Ebola en Afrique : Découvertes au cours des dix dernières années
Authors: R R Arthur
Journal: Eurosurveillance (2002)

La fievre hemorragique Ebola (FHE) a ete reconnue pour la premiere fois dans quatre pays au cours des dix dernieres annees. Nos connaissances de l’epidemiologie, des aspects cliniques, du diagnostic de laboratoire et des mesures de controle de la FHE ont ete considerablement ameliorees a la suite des epidemies dans ces pays et de la re-emergence de cette maladie survenue dans un autre. Les reponses internationales coordonnees a plusieurs epidemies importantes de FHE ont servi de modele pour controler les epidemies d’autres maladies transmissibles. Cet article propose une revue chronologique des flambees de FHE en Afrique au cours des dix dernieres annees, y compris les recentes epidemies au Gabon et dans la Republique du Congo. Il met en evidence de nouvelles decouvertes, ainsi que certains des defis a affronter.
Sleep Duration and Quality: Impact on Lifestyle Behaviors and Cardiometabolic Health: A Scientific Statement From the American Heart Association
Authors: Marie-Pierre St-Onge, Michael A. Grandner, Devin Brown, Molly B. Conroy, Girardin Jean-Louis, Michael Coons, Deepak L. Bhatt
Journal: Circulation (2016)

Sleep is increasingly recognized as an important lifestyle contributor to health. However, this has not always been the case, and an increasing number of Americans choose to curtail sleep in favor of other social, leisure, or work-related activities. This has resulted in a decline in average sleep duration over time. Sleep duration, mostly short sleep, and sleep disorders have emerged as being related to adverse cardiometabolic risk, including obesity, hypertension, type 2 diabetes mellitus, and cardiovascular disease. Here, we review the evidence relating sleep duration and sleep disorders to cardiometabolic risk and call for health organizations to include evidence-based sleep recommendations in their guidelines for optimal health.
Abstract IA40: Patient-derived tumorgrafts from primary peripheral T-cell lymphoma represent innovative models to design patients' tailored therapies.
Authors: Giorgio Inghirami
Journal: Clinical Cancer Research (2015)

Abstract Peripheral T-cell Lymphoma (PTCL) are a heterogeneous group of tumors with a dismal clinical outcome. The poor response of PTCL patients to conventional treatments is in part due to the lack of known pathogenetic mechanisms and reliable/reproducible in vitro or in vivo models. To overcome some of these limitations, we have constructed a library of Patient Derived Tumografts (PDT) from Anaplastic Large Cell Lymphoma patients in highly immunocompromised mice (NSG). Engraftment lymphoma were serially propagated and interrogated by using massive parallel sequencing platforms [RNAseq and WES], and by additional genomic and immunophenotype strategies. Our data demonstrate conserved similarities between PDT and their corresponding primary lymphoma and the presence of novel recurrent somatic lesions. Co-clinical trials of PDT bearing mice showed responses to therapies analogous to those seen in donor patients and could predict alternative and more successful therapeutic strategies. ALCL PDT represent informative models to discover patient restricted/pathogenetic lesions and to design more efficient and/or tailored therapies for naïve and chemorefractory PTCL individuals. Citation Format: Giorgio Inghirami. Patient-derived tumorgrafts from primary peripheral T-cell lymphoma represent innovative models to design patients' tailored therapies. [abstract]. In: Proceedings of the AACR Special Conference on Hematologic Malignancies: Translating Discoveries to Novel Therapies; Sep 20-23, 2014; Philadelphia, PA. Philadelphia (PA): AACR; Clin Cancer Res 2015;21(17 Suppl):Abstract nr IA40.
Long-term Impact of Adjuvant Versus Early Salvage Radiation Therapy in pT3N0 Prostate Cancer Patients Treated with Radical Prostatectomy: Results from a Multi-institutional Series
Authors: Nicola Fossati, R. Jeffrey Karnes, Stephen A. Boorjian, Marco Moschini, Alessandro Morlacco, Alberto Bossi, Thomas Seisen, Cesare Cozzarini, Claudio Fiorino, Barbara Noris Chiorda, Giorgio Gandaglia, Paolo Dell’Oglio, Steven Joniau, Lorenzo Tosco, Shahrokh Shariat, Gregor Goldner, Wolfgang Hinkelbein, Detlef Bartkowiak, Karin Haustermans, Bertrand Tombal, Francesco Montorsi, Hein Van Poppel, Thomas Wiegel, Alberto Briganti
Journal: European Urology (2016)
Case 22-2016
Authors: Stephanie A. Moore, Suhny Abbara, Gary S. Mak, Eugene J. Mark, James R. Stone
Journal: New England Journal of Medicine (2016)

A 65-year-old man presented with syncope. One month earlier, cough, dyspnea, and leg edema had developed. Imaging studies of the chest revealed lymphadenopathy, and an echocardiogram showed hypertrophic obstructive cardiomyopathy. A diagnostic procedure was performed.
Abstract 3668: Investigating a tumor suppressor role for Parkinson's susceptibility gene LRRK2 in lung cancer
Authors: Chandra Lebovitz, Norman Chow, Wan Lam, Sharon Gorski
Journal: Cancer Research (2016)

Abstract In this study we investigate a novel and previously untested research question: does a known disease susceptibility gene in Parkinson's disease (PD) also act as a tumor suppressor gene in lung cancer? Our screen of publicly available cancer patient sequence data for genome and transcriptome alterations of genes that modulate autophagy, an important tumor cell survival process, revealed a dramatic loss of gene expression of Leucine-rich repeat kinase 2 (LRRK2) in non-small cell lung tumors compared to matched normal tissue. We further confirmed reduced or absent LRRK2 protein expression in a panel of lung cancer cell lines. Activating kinase-domain mutations in LRRK2 and their effect on autophagy in neuronal cell types is under study in PD; however, the pathological role of altered LRRK2 in cancer and its effect on autophagy status and tumorigenicity is completely unexplored. Pharmacological inhibition of the LRRK2 kinase domain was recently shown to stimulate autophagy in PD cell lines, while many tumors are thought to exploit elevated autophagy to survive metabolic stress and chemotherapy. Ongoing clinical trials are testing combination autophagy inhibition with current standard of care treatments in multiple cancers. Therefore, a better understanding of pathogenic LRRK2-mediated autophagy in lung cancer could form the basis of a new approach to help identify lung cancer patients that may benefit from treatment strategies employing autophagy inhibitors. Our preliminary data indicates that LRRK2 knockdown in lung cancer cell lines leads to altered cellular phenotypes and increased protein levels of a known lung cancer gene. We are further testing whether genetic and/or pharmacological inhibition of LRRK2 facilitates tumorigenesis in standard murine models of lung cancer. Our investigation of the biological relevance and therapeutic potential of a surprising discovery linking neurodegenerative disease-associated LRRK2 and lung cancer may uncover a new tumor suppressor gene and provide a novel marker (i.e. LRRK2 loss) to aid in lung cancer detection. Citation Format: Chandra Lebovitz, Norman Chow, Wan Lam, Sharon Gorski. Investigating a tumor suppressor role for Parkinson's susceptibility gene LRRK2 in lung cancer. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 3668.
Risk Factors for Blood Product Usage Following Sibling Allogeneic Haemopoietic Stem Cell Transplantation (allo-HCT).
Authors: Nicola Hurst, Charles G. Mullighan, Sue L. Heatley, Kathryn Robinson, Silke Danner, Uwe Hahn, Jeff Szer, Peter Shuttleworth, Rosie Hoyt, Anthony P. Schwarer, Jenny Muirhead, Kenneth Bradstock, Lisa Miller, Peter G. Bardy
Journal: Blood (2007)
P0286 : C-MET signaling contributes to carcinogenesis of cholangiocarcinoma and is blocked by LY2801653, a small molecule inhibitor
Authors: S. Barat, P. Bozko, X. Chen, T. Scholta, F. Hanert, J. Götze, N. Malek, L. Wilkens, R. Plentz
Journal: Journal of Hepatology (2015)
Abstract 2511: Association of ALDH1A1 with cisplatin resistance via modulation of NEK-2 in ovarian cancer stem-like cells
Authors: Md. Hafiz Uddin, Yong Sang Song
Journal: Cancer Research (2016)

Abstract Cisplatin (CDDP) resistance is the foremost obstacle in the treatment of ovarian cancer patients. According to the cancer stem cell hypothesis, the recurrence and chemoresistance are presumed to be linked to cancer stem/progenitor cells. Here, we investigated the cancer stem cell like phenotypes and mechanism of chemoresistance in CDDP resistant ovarian cancer cells. A well-established CDDP sensitive ovarian cancer cell line A2780 and its resistant clone A2780 Cp were used and we also developed a supra resistant clone (SKOV3 Cp) from a naturally CDDP resistant cell line SKOV3 by six shocks treatment. Sensitiveness to CDDP was evaluated by MTT assay and self renewal efficiency by sphere formation, noble agar and clonogenic assays. A few cancer hallmarks and stem-cell markers were characterized using flow cytometry. Molecular analysis was performed using quantitative PCR and western blotting. For the silencing of selected genes small interfering RNA (siRNA) based approaches was utilized. Both CDDP resistant A2780 Cp and supra resistant SKOV3 Cp cell lines showed significantly (P &amp;lt; 0.05) higher self-renewal ability in sphere formation, noble agar and clonogenic assays than their parental counterparts. They also showed significant resistance to apoptosis and sub-G1 arrest upon CDDP treatment. Stem cell marker ALDH1 positivity rates were higher both in A2780 Cp and SKOV3 Cp cell lines, quantified by ALDEFLUORTM assay kit using flow cytometry. Hoechst 33342 dye effluxing side populations were increased about five folds in A2780 Cp cells and two folds in SKOV3 Cp cells compared to A2780 and SKOV3 cells respectively. Among major stemness related genes (OCT4, SOX2, NANOG, NESTIN, BMI1, KLF4 and ALDH1A1) quantitative PCR analysis showed significantly higher expression of ALDH1A1 and KLF4 genes in both resistant and supra resistant cells than their parental clones. Of two genes, silencing ALDH1A1 in A2780 and A2780 Cp cells using siRNA greatly reduced the stem cell population as detected by ALDEFLUORTM assay and sensitized cells to CDDP. Moreover, silencing of ALDH1A1 reduce the level of its downstream target NEK-2. We also observed the downregulation of ABC transporters (ABCB1, ABCG2 and ABCC1) by silencing either ALDH1A1 or NEK-2 gene. Taken together, present study showed for the first time that stemness gene ALDH1A1 can be involved in CDDP resistance via the upregulation of NEK-2 in ovarian or solid cancer. Citation Format: Md. Hafiz Uddin, Yong Sang Song. Association of ALDH1A1 with cisplatin resistance via modulation of NEK-2 in ovarian cancer stem-like cells. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 2511.
Abstract 2245: FDG PET quantification for prediction of early recurrence in patients with stage I and II non small cell lung cancer
Authors: Irene A. Burger, Michael Arvanitakis, Seraina Steiger, Walter Weder, Sven Hillinger
Journal: Cancer Research (2016)

Abstract Background: Although surgical resection remains the optimal treatment for early-stage NSCLC, up to 50% of patients with stage I and II relapse and die within 5 years after curative resection. Therefore prognostic markers are important as these patients might benefit from adjuvant therapy. The goal of this study was to evaluate established PET quantification metrics including: maximal standard uptake volume (SUVmax), metabolic tumor volume (MTV) and total lesion glycolysis (TLG) as prognostic markers for early recurrence and overall survival in resected early stage lung cancer. Methods: Between January 2003 and December 2010 182 surgically resected patients with stage I-II NSCLC who underwent 18 F FDG PET/CT less than one month prior to surgery have been evaluated. All patients had at least 5 years of follow-up. Cox proportional hazard model was used to determine the association between variables and survival respectively time to recurrence. For the multivariate analysis the following variables have been included: tumor size on CT, age tumor stage, histology, SUVmax, TLG (for TLG42% (threshold at 42% SUVmax) and TLG2.5 (cut-off at SUV 2.5) and MTV42% and MTV2.5). Results: 133 patients were included, 71 with adeno carcinoma, 62 with squamous cell carcinoma. TLG2.5 and MTV2.5 values have been a significant prognostic factor for recurrence (P&amp;lt;0.0001). Patients with a MTV2.5 above 42 cm3 had a mean recurrence time of 0.8±0.9 years, while patients with MTV2.5 ≤ 42 cm3 recurred within 2.8±1.3 years. TLG2.5 and MTV2.5 PET volume metrics have not been predictable for overall survival in adenocarcinoma patients, recurrence or overall survival in squamous cell cancer. SUVmax, TLG42% and MTV42 were not predictable for early recurrence or survival for both histologies. Conclusions: TLG2.5 and MTV2.5 may be useful prognostic variables in stage I-II NSCLC depending on the tumor type. Using a cut-off at 42 cm3 for early stage adenocarcinoma patients a high risk of recurrence within one year might be identified and adjuvant therapy following surgical resection could improve outcome for those patients. Citation Format: Irene A. Burger, Michael Arvanitakis, Seraina Steiger, Walter Weder, Sven Hillinger. FDG PET quantification for prediction of early recurrence in patients with stage I and II non small cell lung cancer. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 2245.
Alloimmunity to Erythrocytes in Patients during Pregnancy in South Korea and Japan; Recent Results from a Cooperative International Study of Alloimmunity to Antigen Diversity in Asian Populations
Authors: Miwa Adachi, Akihiro Takeshita, Dae Won Kim, Kyou Sup Han, So-Yong Kwon, Hyun Ok Kim, Jang Soo Suh, Hiroko Watanabe, Makoto Uchikawa, Shuichi Kino, Hitoshi Ohto
Journal: Blood (2014)
Effects of Cannabis Use on Human Behavior—Reply
Authors: Nora D. Volkow
Journal: JAMA Psychiatry (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Psychiatry HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Psychiatry journal
Abstract 2404: Dysregulation of lung developmental pathways associated with LKB1 loss in lung cancer
Authors: Jacob M. Kaufman, Cindy Lowe, Bradford Harris, Kelli Boyd, Joseph Amann, Rosana Eisenberg, David Carbone, Pierre Massion
Journal: Cancer Research (2016)

Abstract Loss of the LKB1 tumor suppressor influences differentiation phenotypes in mouse models of lung adenocarcinoma and in human tumors. We utilize molecular data from resected human lung adenocarcinomas characterized by the TCGA to demonstrate that LKB1 deficient tumors exhibit a higher prevalence of neuroendocrine and gut-like differentiation markers than do LKB1 wild-type tumors (41% vs 9%, odds ratio = 7.3, P = 5.9E-19 for neuroendocrine differentiation; 36% vs 12%, odds ratio = 4.3, P = 2.5E-11 for gut-like differentiation. Fisher's exact test). Using copy number analysis and transcription factor enrichment analysis, we link these phenotypes to activation of particular transcription factors, namely FOXA2, HNF1A, ASCL1, and TTF1. We observe similar associations among non-small cell lung cancer cell lines, which may represent appropriate ideal models for further experimentation. Furthermore, we examine these differentiation phenotypes using immunohistochemical analysis of a tissue microarray (TMA), combined with RNAseq expression analysis, and MS/MS proteomic characterization of the same cohort of 36 tumors. Our molecular characterization confirms the neuroendocrine and gut-like differentiation phenotypes observed in the TCGA dataset and their association with LKB1-loss. Moreover, our immunohistochemical analysis demonstrates that these distinct differentiation subtypes are heterogeneously expressed within single tumors. Co-expression of neuroendocrine, gut-like, and respiratory differentiation is significantly more likely to occur within LKB1 deficient tumors, and is also associated with increased expression of a c-Kit positive sub-population that appears to lack expression of more differentiated markers. Among the TCGA tumors, this tri-lineage expression pattern is seen in 12.5% of LKB1-deficient tumors, compared to 1% of LKB1-wild-type tumors (Odds ratio 11.5, P = 3.2E-8. Fisher's exact test). These findings give further support to the role of LKB1 in regulating differentiation phenotypes in lung cancer, and may suggest a hierarchy of progenitor cells and lineage-specific subpopulations within these tumors. Citation Format: Jacob M. Kaufman, Cindy Lowe, Bradford Harris, Kelli Boyd, Joseph Amann, Rosana Eisenberg, David Carbone, Pierre Massion. Dysregulation of lung developmental pathways associated with LKB1 loss in lung cancer. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 2404.
Endoscopic esophageal perforation extending upwards along the carotid arteries
Authors: Yalaka Reddy, Pankaj Gupta, Sarthak Malik, Bipada Mallick, Anupam Lal, Saroj Sinha, Rakesh Kochhar
Journal: Endoscopy (2016)

A 21-year-old man presented to gastroenterology services with progressive dysphagia, 6 weeks after ingestion of dichlorvos (2,2-dichlorovinyl dimethyl phosphate), an organophosphate insecticide used to control household pests. Barium swallow revealed a long stricture involving the middle and lower thirds of the esophagus. The difficulties, complications, and failure rates of endoscopic dilation for long strictures were explained to the patient, and surgery was advised. However, the patient wanted a trial of endoscopic management prior to surgery.
Surveillance du VIH/SIDA en Europe : données actualisées à fin 2000
Authors: F F Hamers, J Alix, C Semaille, H Pilkington, A M Downs
Journal: Eurosurveillance (2001)

Dans la zone Ouest de l'Europe, l'incidence du sida a diminue de 12% en 2000 par rapport a 1999 (22 cas par million d'habitants). Dans la zone Est, l'incidence des cas declares est restee faible, mais on observe une augmentation des infections nouvellement diagostiquees. Dans la zone Centre, le taux des cas de sida et des infections a VIH demeure faible